Skip to main content

Table 2 Patient and dosimetry characteristics after propensity score matching

From: Stereotactic body radiation therapy for prostate cancer: a study comparing 3-year genitourinary toxicity between CyberKnife and volumetric-modulated arc therapy by propensity score analysis

Parameter

CyberKnife (n = 35)

VMAT (n = 35)

p Value

Age (years)

71.7 ± 6.3

71.8 ± 5.8

0.953

Clinical T stage

0.50

1c-2a

14 (40%)

18 (51%)

 

2b-2c

14 (40%)

9 (26%)

 

3a

7 (20%)

8 (23%)

 

IPSA (ng/mL)

0.70

 < 10

20 (57%)

23 (66%)

 

10–20

10 (29%)

7 (20%)

 

 > 20

5 (14%)

5 (14%)

 

Gleason score

0.775

6

3 (8%)

5 (14%)

 

7

24 (69%)

21 (60%)

 

8–10

8 (23%)

9 (26%)

 

Risk group

0.82

Low

2 (5.7%)

4 (11.4%)

 

Intermediate

19 (54.3%)

17 (48.6%)

 

High

14 (40%)

14 (40%)

 

Neoadjuvant ADT

33 (94.3%)

31 (88.6%)

0.673

Duration of neoadjuvant ADT (months)

6.4 ± 3.2

6.3 ± 0.8

0.867

Comorbidity

 

Antithrombotic therapy

5 (14.3%)

6 (17.1%)

0.99

Diabetes

5 (14.3%)

4 (11.4%)

0.99

Previous TURP

0 (0%)

1 (2.9%)

0.99

Medication to improve dysuria at baseline

7 (20%)

7 (20%)

0.99

Pre-treatment IPSS

0.939

Mild (0–7)

10 (28.6%)

12 (34.3%)

 

Moderate (8–19)

21 (60.0%)

19 (54.3%)

 

Severe (20–35)

4 (11.4%)

4 (11.4%)

 

Median follow-up (years)

3.0 (1.1–4.6)

2.9 (1.6–4.2)

0.36

Prostate volume (cc)

25.3 ± 9.3

25.3 ± 15.5

0.997

PTV volume (cc)

47.3 ± 13.0

62.4 ± 23.9

0.002

PTV D98% (Gy)

35.4 ± 0.30

35.8 ± 0.15

 < 0.001

PTV Dmedian (Gy)

41.8 ± 0.76

37.1 ± 0.20

 < 0.001

PTV D2% (Gy)

44.0 ± 0.80

37.7 ± 0.24

 < 0.001

Bladder volume (cc)

191.0 ± 44.8

237.5 ± 102.5

0.0165

Bladder Dmean (Gy)

9.75 ± 1.64

9.74 ± 2.43

0.979

Bladder D0.5 cc (Gy)

39.7 ± 1.10

37.5 ± 0.18

 < 0.001

Bladder Dmax (Gy)

41.9 ± 1.40

37.8 ± 0.19

 < 0.001

Urethra Dmean (Gy)

36.0 ± 0.18

37.1 ± 0.30

 < 0.001

Urethra D0.1 cc (Gy)

36.2 ± 0.22

37.4 ± 0.37

 < 0.001

Urethra Dmax (Gy)

37.1 ± 0.40

37.5 ± 0.40

0.002

Rectal Dmean (Gy)

9.80 ± 1.75

9.80 ± 1.76

0.99

Rectal D0.5 cc (Gy)

35.6 ± 1.45

36.3 ± 1.31

0.034

Rectal Dmax (Gy)

38.9 ± 0.89

37.4 ± 0.50

 < 0.001

  1. Data are presented as median (range), mean ± SD, or number (%)
  2. VMAT volumetric modulated arc therapy; IPSA initial prostate-specific antigen; ADT androgen deprivation therapy; TURP transurethral resection of the prostate; IPSS International Prostate Symptom Score; PTV planning target volume; Dmedian median dose; Dx% dose covering x% of the target volume; Dmean mean dose; Dx cc dose to x cc of the organ; Dmax maximum dose